SCI Pharmtech, Inc. - Laporan Laba Rugi (TTM)

SCI Pharmtech, Inc.
TW ˙ TWSE ˙ TW0004119003
NT$ 60.50 ↓ -0.70 (-1.14%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi SCI Pharmtech, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 2,711 2,689 2,229 1,677 1,227 864 729 733 810 900 1,053 1,185 1,139 1,204 1,172 1,252 1,413 1,524 1,574 1,553
Change (%) -0.80 -17.13 -24.74 -26.87 -29.54 -15.69 0.66 10.41 11.11 17.09 12.51 -3.94 5.77 -2.65 6.79 12.90 7.81 3.31 -1.35
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,492 1,415 1,217 1,012 796 656 561 541 598 609 694 807 773 854 853 904 1,030 1,113 1,176 1,159
Change (%) -5.16 -14.00 -16.80 -21.37 -17.57 -14.47 -3.69 10.64 1.77 14.12 16.14 -4.20 10.50 -0.09 6.03 13.89 8.06 5.67 -1.46
% of Revenue 55.03 52.61 54.60 60.36 64.89 75.92 77.02 73.70 73.85 67.64 65.92 68.05 67.87 70.91 72.77 72.25 72.89 73.05 74.72 74.64
Gross Operating Profit 1,219 1,274 1,012 665 431 208 167 193 212 291 359 379 366 350 319 347 383 411 398 394
Change (%) 4.53 -20.60 -34.28 -35.23 -51.68 -19.55 15.22 9.77 37.52 23.30 5.48 -3.40 -4.24 -8.89 8.83 10.32 7.16 -3.10 -1.02
% of Revenue 44.97 47.39 45.40 39.64 35.11 24.08 22.98 26.30 26.15 32.36 34.08 31.95 32.13 29.09 27.23 27.75 27.11 26.95 25.28 25.36
SG&A 233 179 143 89 67 104 101 113 120 133 136 133 127 141 145 156 180 170 168 162
Change (%) -23.03 -20.36 -37.42 -25.20 55.63 -2.85 11.80 6.21 10.41 2.85 -2.46 -4.34 10.78 2.81 7.85 15.48 -5.97 -0.72 -4.13
% of Revenue 8.60 6.67 6.41 5.33 5.45 12.04 13.88 15.41 14.83 14.73 12.94 11.22 11.17 11.70 12.36 12.48 12.77 11.14 10.70 10.40
R&D 42 43 40 37 33 30 32 35 37 40 43 45 49 49 48 46 43 43 42 40
Change (%) 3.27 -7.39 -9.03 -10.08 -7.63 4.67 11.25 4.20 7.69 8.86 4.81 8.31 0.20 -2.76 -4.03 -6.55 -0.32 -1.86 -3.33
% of Revenue 1.55 1.61 1.80 2.18 2.68 3.51 4.36 4.82 4.55 4.41 4.10 3.82 4.30 4.08 4.07 3.66 3.03 2.80 2.66 2.61
OpEx 1,767 1,638 1,400 1,138 896 791 694 689 755 781 874 985 949 1,044 1,046 1,107 1,253 1,325 1,387 1,361
Change (%) -7.32 -14.52 -18.69 -21.31 -11.74 -12.20 -0.75 9.58 3.43 11.94 12.68 -3.64 10.01 0.18 5.82 13.26 5.75 4.61 -1.84
% of Revenue 65.18 60.90 62.81 67.87 73.02 91.48 95.26 93.93 93.23 86.78 82.96 83.08 83.35 86.69 89.20 88.40 88.68 86.99 88.08 87.64
Operating Income 944 1,052 829 539 331 74 35 45 55 119 180 200 190 160 127 145 160 198 188 192
Change (%) 11.39 -21.19 -34.97 -38.60 -77.74 -53.12 28.89 23.25 116.90 50.90 11.68 -5.43 -15.46 -21.05 14.80 10.09 23.98 -5.40 2.30
% of Revenue 34.82 39.10 37.19 32.13 26.98 8.52 4.74 6.07 6.77 13.22 17.04 16.92 16.65 13.31 10.80 11.60 11.32 13.01 11.92 12.36
Interest Expense -0 -0 -0 -0 -0 -0 -0 -1 -1 -1 -3 -4 -5 -6 -6 -6 -6 -6 -5 -5
Change (%) -4.44 -2.33 7.14 -4.44 -4.65 146.34 468.32 11.15 68.03 152.71 51.35 27.02 20.78 -3.29 -8.70 7.99 -7.64 -11.70 -4.03
% of Revenue -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.01 -0.08 -0.08 -0.12 -0.26 -0.35 -0.46 -0.52 -0.52 -0.44 -0.42 -0.36 -0.31 -0.30
Net Income 728 360 193 -44 -203 56 55 192 210 309 331 390 377 295 276 138 484 535 522 482
Change (%) -50.56 -46.28 -122.98 357.67 -127.38 -0.90 247.47 9.75 46.70 7.21 17.88 -3.39 -21.82 -6.42 -49.79 249.71 10.42 -2.39 -7.55
% of Revenue 26.87 13.39 8.68 -2.65 -16.59 6.44 7.58 26.15 25.99 34.32 31.42 32.92 33.11 24.48 23.53 11.06 34.26 35.09 33.15 31.07

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista